Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy
Thomas S. Uldrick(Regeneron (United States)), Sharon R. Lewin(Peter Doherty Institute), Rémi Fromentin(Centre Hospitalier de l’Université de Montréal), Robert J. Gorelick(Frederick National Laboratory for Cancer Research), Kathryn Lurain(The Ohio State University), Steven P. Fling(Fred Hutch Cancer Center), Scott V. Adams(Fred Hutch Cancer Center), Jorden L. Welker(Frederick National Laboratory for Cancer Research), Rafick‐Pierre Sékaly(University Hospitals of Cleveland), Robert Yarchoan(National Cancer Institute), Harleen Choudhary(Fred Hutch Cancer Center), Jeffrey D. Lifson(Science Applications International Corporation (United States)), Liz O’Donoghue(Fred Hutch Cancer Center), Ajantha Rhodes(The University of Melbourne), Steven G. Deeks(University of California, San Francisco), Frank Maldarelli(Cancer Institute (WIA)), Chia-Ching Jackie Wang(University of California, San Francisco), Nicolas Chomont(Vaccine & Gene Therapy Institute of Florida), Carolin Tumpach(Peter Doherty Institute), Ramya Ramaswami(National Cancer Institute), Michael Roche(The University of Melbourne), Thomas A. Rasmussen(Aarhus University Hospital), Priscila Gonçalves(The Barbara Ann Karmanos Cancer Institute), Martin A. Cheever(Johns Hopkins University)
Cited by 101
Related Papers
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
|Clinical Cancer Research|2009|1.4k
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
|New England Journal of Medicine|2009|1.1k
Systemic Effects of Inflammation on Health during Chronic HIV Infection
|Immunity|2013|835
Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load
|Blood|2004|787
Defective proviruses rapidly accumulate during acute HIV-1 infection
|Nature Medicine|2016|774